Head to head
Lumexa Imaging vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: LMRI · ABT
LMRI
Lumexa Imaging
10.24-3.31%
1-year price shape — not enough history yet
Quant Rating C · 59/100
vs
ABT
Abbott Laboratories
98.36-0.37%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| LMRI | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 10.24 | 98.36 |
| Change today | -3.31% | -0.37% |
| 1-year return | -- | -24.1% |
| Market cap | $983.81M | $170.20B |
| 52-week range | 6.45 – 19.45 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -35.43 | 31.83 |
| P/E percentile, own 5-yr range | 23rd | 62nd |
| P/B | 1.60 | 3.33 |
| Dividend yield | 0.00% | 2.48% |
| Profitability & growth | ||
| EPS (TTM) | -0.49 | 3.72 |
| Net profit (TTM) | $-47.08M | $6.44B |
| Revenue (TTM) | $1.04B | $46.59B |
| Revenue growth (YoY) | +5.1% | +13.0% |
| Gross margin | 14.9% | 56.6% |
| Operating margin | 1.4% | 15.8% |
| Net margin | -2.7% | 11.6% |
| Free cash flow (TTM) | $31.24M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 112.8% | 81.2% |
| Insider activity (12mo) | 19 buy / 0 sell | 36 buy / 12 sell |
| Short interest (% of float) | 2.2% | 1.1% |
| Analyst consensus | 100% buy (7) | 100% buy (14) |
| Analyst price target | $17 (+68%) | $125 (+27%) |
| StockVane view | ||
| StockVane Quant Rating | C (59) | E (15) |
| Company | ||
| Employees | 5,019 | 115,000 |
| Founded | -- | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.